cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma
- PMID: 15380028
- PMCID: PMC520814
- DOI: 10.1186/1471-2164-5-70
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma
Abstract
Background: Recurrent non-random genomic alterations are the hallmarks of cancer and the characterization of these imbalances is critical to our understanding of tumorigenesis and cancer progression.
Results: We performed array-comparative genomic hybridization (A-CGH) on cDNA microarrays containing 42,000 elements in neuroblastoma (NB). We found that only two chromosomes (2p and 12q) had gene amplifications and all were in the MYCN amplified samples. There were 6 independent non-contiguous amplicons (10.4-69.4 Mb) on chromosome 2, and the largest contiguous region was 1.7 Mb bounded by NAG and an EST (clone: 757451); the smallest region was 27 Kb including an EST (clone: 241343), NCYM, and MYCN. Using a probabilistic approach to identify single copy number changes, we systemically investigated the genomic alterations occurring in Stage 1 and Stage 4 NBs with and without MYCN amplification (stage 1-, 4-, and 4+). We have not found genomic alterations universally present in all (100%) three subgroups of NBs. However we identified both common and unique patterns of genomic imbalance in NB including gain of 7q32, 17q21, 17q23-24 and loss of 3p21 were common to all three categories. Finally we confirm that the most frequent specific changes in Stage 4+ tumors were the loss of 1p36 with gain of 2p24-25 and they had fewer genomic alterations compared to either stage 1 or 4-, indicating that for this subgroup of poor risk NB requires a smaller number of genomic changes are required to develop the malignant phenotype.
Conclusions: cDNA A-CGH analysis is an efficient method for the detection and characterization of amplicons. Furthermore we were able to detect single copy number changes using our probabilistic approach and identified genomic alterations specific to stage and MYCN amplification.
Figures





Similar articles
-
Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.Mol Diagn. 2004;8(2):93-100. doi: 10.1007/BF03260051. Mol Diagn. 2004. PMID: 15527323
-
Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.Genes Chromosomes Cancer. 2008 Oct;47(10):819-34. doi: 10.1002/gcc.20583. Genes Chromosomes Cancer. 2008. PMID: 18553563
-
A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.Cancer Lett. 2013 Apr 30;331(1):115-21. doi: 10.1016/j.canlet.2012.12.011. Epub 2012 Dec 23. Cancer Lett. 2013. PMID: 23268333
-
Gene profiling of high risk neuroblastoma.World J Surg. 2005 Mar;29(3):317-24. doi: 10.1007/s00268-004-7820-7. World J Surg. 2005. PMID: 15706435 Review.
-
Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis.Br J Cancer. 2020 Mar;122(7):1077-1084. doi: 10.1038/s41416-020-0740-y. Epub 2020 Feb 4. Br J Cancer. 2020. PMID: 32015512 Free PMC article.
Cited by
-
A unique cytogenetic abnormality, t(2;7)(p13.1;p21.3), in a Philadelphia-positive chronic myeloid leukemia.Oncol Lett. 2012 Aug;4(2):209-212. doi: 10.3892/ol.2012.720. Epub 2012 May 17. Oncol Lett. 2012. PMID: 22844355 Free PMC article.
-
Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.Virchows Arch. 2008 Jul;453(1):47-55. doi: 10.1007/s00428-008-0633-6. Epub 2008 Jun 24. Virchows Arch. 2008. PMID: 18574593
-
Fast detection of MYCN copy number alterations in brain neuronal tumors by real-time PCR.J Clin Lab Anal. 2008;22(2):123-30. doi: 10.1002/jcla.20232. J Clin Lab Anal. 2008. PMID: 18348317 Free PMC article.
-
Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.PLoS One. 2014 Jul 11;9(7):e101990. doi: 10.1371/journal.pone.0101990. eCollection 2014. PLoS One. 2014. PMID: 25013904 Free PMC article.
-
A small subunit processome protein promotes cancer by altering translation.Oncogene. 2015 Aug 20;34(34):4471-81. doi: 10.1038/onc.2014.376. Epub 2014 Dec 1. Oncogene. 2015. PMID: 25435373
References
-
- Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, Moley J, Nakagawara A, Saylors R, Scavarda N, et al. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer. 1992;70:1685–94. - PubMed
-
- Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Boecker W, Lampert F, Stoerkel S. Comparative genomic hybridization (CGH) analysis of neuroblastomas--an important methodological approach in paediatric tumour pathology. J Pathol. 1997;181:394–400. doi: 10.1002/(SICI)1096-9896(199704)181:4<394::AID-PATH800>3.3.CO;2-T. - DOI - PubMed
-
- Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Benard J, et al. Comparative genomichybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001;91:680–6. doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous